| 1 |
Clinical development and global collaboration of NS101: A novel monoclonal antibody therapeutic for sensorineural hearing loss through synaptic restoration |
| Antibody |
sudden sensorineural hearing loss |
FAM19A5 |
Phase 1 |
Neuracle Science. Co., Ltd. |
RS-2024-00332473 |
|
| 2 |
Phase 1 clinical development of TU7710, bypassing agent for hemophilia with prolonged half life. |
| rProtein |
Haemophilia A, B |
recombinant coagulation factor VIIa |
Phase 1 |
TiumBio Co., Ltd. |
RS-2023-00282592 |
|
| 3 |
Phase 1a clinical trial and approval of IND for phase 1b/2a clinical trial of androgenic alopecia therapeutics using cell.penetrating RNAi gene regulation technology |
| Gene & Nucleic acids |
Androgenetic alopecia |
androgen receptor |
Phase 1 |
Olix Pharmaceuticals |
RS-2023-00259300 |
|
| 4 |
Phase 1 clinical trial of recombinant hyaluronidase ALT-BB4 |
| rProtein |
N/A |
Hyaluronidase |
Phase 1 |
Alteogen Inc. |
HN22C0112 |
|